Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK7 | P50613 | 2/20 | 0.45 |
| ▸ | CDC7 | O00311 | 1/20 | 0.45 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.45 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.45 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.45 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.45 |
| ▸ | PAK4 | O96013 | 1/20 | 0.45 |
| ▸ | PIM1 | P11309 | 1/20 | 0.45 |
| ▸ | PRKACA | P17612 | 1/20 | 0.45 |
| ▸ | CDK2 | P24941 | 1/20 | 0.45 |
| ▸ | FLT3 | P36888 | 1/20 | 0.45 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.45 |
| ▸ | CDK8 | P49336 | 1/20 | 0.45 |
| ▸ | CLK2 | P49760 | 1/20 | 0.45 |
| ▸ | CDK9 | P50750 | 1/20 | 0.45 |
| ▸ | PRKX | P51817 | 1/20 | 0.45 |
| ▸ | JAK3 | P52333 | 1/20 | 0.45 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.45 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.45 |
| ▸ | STK3 | Q13188 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18108681 | 0.85 | AURKA (0.56) | CDC7PAK4PRKACAFLT3JAK3 | |
| SCHEMBL18108625 | 0.84 | AURKA (0.59) | FLT3NTRK1AURKAINSRIGF1R | |
| SCHEMBL18108645 | 0.83 | TTK (0.56) | CDK7CDC7DAPK3ROCK2PRKD3 | |
| SCHEMBL18120884 | 0.83 | CDK7 (0.46) | CDK7CDC7DAPK3ROCK2PRKD3 | |
| SCHEMBL18108756 | 0.81 | MAPK1 (0.61) | CDK7CDC7DAPK3ROCK2PRKD3 | |
| SCHEMBL18108595 | 0.80 | MAPK1 (0.60) | CDK7CDC7DAPK3ROCK2PRKD3 | |
| SCHEMBL18120885 | 0.80 | NPC1 (0.57) | CDK7CDC7DAPK3ROCK2PRKD3 | |
| Trifluoroacetic Acid SCHEMBL18108590 | 0.79 | CDK7 (0.44) | CDK7CDC7DAPK3ROCK2PRKD3 | |
| SCHEMBL18108549 | 0.79 | CDK7 (0.49) | CDK7CDC7DAPK3ROCK2PRKD3 | |
| SCHEMBL18108698 | 0.79 | CDK7 (0.45) | CDK7CDC7DAPK3ROCK2PRKD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10294207-B2 | Pyrazole derivatives as TNIK, IKKϵ and TBK1 inhibitor and pharmaceutical composition comprising same | GREEN CROSS CORPORATION (KR) | 2019-05-21 | — | — | US | claimed |
| US-20160289196-A1 | PYRAZOLE DERIVATIVES AS TNIK, IKKe AND TBK1 INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | GREEN CROSS CORPORATION (KR) | 2016-10-06 | — | — | US | claimed |
| US-10294207-B2 | Pyrazole derivatives as TNIK, IKKϵ and TBK1 inhibitor and pharmaceutical composition comprising same | GREEN CROSS CORPORATION (KR) | 2019-05-21 | — | — | US | disclosed |
| US-10294207-B2 | Pyrazole derivatives as TNIK, IKKϵ and TBK1 inhibitor and pharmaceutical composition comprising same | GREEN CROSS CORPORATION (KR) | 2019-05-21 | — | — | US | disclosed |
| US-20160289196-A1 | PYRAZOLE DERIVATIVES AS TNIK, IKKe AND TBK1 INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | GREEN CROSS CORPORATION (KR) | 2016-10-06 | — | — | US | disclosed |
| US-20160289196-A1 | PYRAZOLE DERIVATIVES AS TNIK, IKKe AND TBK1 INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | GREEN CROSS CORPORATION (KR) | 2016-10-06 | — | — | US | disclosed |
| US-20160289196-A1 | PYRAZOLE DERIVATIVES AS TNIK, IKKe AND TBK1 INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | GREEN CROSS CORPORATION (KR) | 2016-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10294207-B2 | Pyrazole derivatives as TNIK, IKKϵ and TBK1 inhibitor and pharmaceutical composition comprising same | TNIK, TNNI3K, TNK1 | CDK7 370/4885CDC7 546/4885DAPK3 228/4885 |
| US-20160289196-A1 | PYRAZOLE DERIVATIVES AS TNIK, IKKe AND TBK1 INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | TNIK, TNNI3K, TNK1 | CDK7 390/4885CDC7 553/4885DAPK3 218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.